To explore the effect of vitamin D supplementation on insulin resistance in a group of Iranian patients with polycystic ovary syndrome and vitamin D deficiency.
INTRODUCTION
Polycystic ovary syndrome (PCOS), initially described in 1935 by Stein and Leventhal, is the most common endocrine disorder among females, affecting approximately 5%-20% of women in their reproductive age, depending on the criteria used (He et al., 2015; Asemi et al., 2015; Firouzabadi et al., 2012) . In Iran, the prevalence of PCOS has been reported to be about 15% (Mehrabian et al., 2011) . PCOS is a heterogeneous androgen excess disorder with different degrees of reproductive and metabolic dysfunctions (He et al., 2015) , and it is characterized by hyperandrogenism, menstrual disorder and polycystic ovaries on ultrasound (Firouzabadi et al., 2012) . Increased serum insulin levels, insulin resistance, glucose intolerance, and dyslipidemia are common among patients with PCOS (He et al., 2015) .
A relatively higher prevalence of vitamin D deficiency (50% to 70%) is found among women with PCOS (Legro et al., 2004) compared to a prevalence of 20%-48% among the general adult population (He et al., 2015; Forrest & Stuhldreher, 2011; Hovsepian et al., 2011; Tangpricha et al., 2002) . New studies have indicated a possible role for vitamin D in insulin secretion, as well as insulin resistance (He et al., 2015; Krul-Poel et al., 2013) . Vitamin D deficiency might play a role in the pathogenesis of metabolic syndrome by increasing insulin synthesis and release, as well as insulin receptor expression (He et al., 2015; Ardabili et al., 2012) . Insufficient vitamin D also disturbs extracellular and intracellular calcium balance, which may result in peripheral insulin resistance (Ardabili et al., 2012; Pittas et al., 2007; Jorde & Figenschau, 2009) . Vitamin D deficiency is also followed by increased renin-angiotensin II expression, which might affect insulin resistance (Rammos et al., 2008) .
Some previous studies have suggested that lower vitamin D levels might increase the risk of insulin resistance and metabolic disorder in women with PCOS, but their results are not conclusive (He et al., 2015; Verdoia et al., 2014; Wehr et al., 2009) . Therefore, the objective of the present study was to evaluate the effects of vitamin D supplementation on insulin resistance among Iranian women with PCOS and vitamin D deficiency.
MATERIALS AND METHODS
The present study was a non-controlled trial involving the pre and post treatment of women in the Taleghani Hospital Tehran, Iran from May 2015 to September 2015. Women between 20 and 40 years of age, with established PCOS based on the Rotterdam criteria, who also had vitamin D deficiency, entered the study. The ethics committee of the Shahid Beheshti University of Medical Sciences, Tehran, Iran, approved the study and all participants gave their written consent before entering the study. The present study complied with the tenets of the declaration of Helsinki. We also registered our study in the Iranian Registry of Clinical Trials with the registration number IRCT2014100619426N1. The exclusion criteria included Cushing's syndrome, adrenal hyperplasia, alcoholism, hyperprolactinemia, hypothyroidism, Diabetes Mellitus, androgen secreting tumors, pregnancy, lactation, and any systemic disorder, which can influence vitamin D levels, including malabsorption syndrome as well as liver and kidney diseases. Patients with a past of using drugs, which might affect the levels of vitamin D, such as calcium and vitamin D supplementation, antiepileptic drugs, oral hypoglycemic drugs and glucocorticoids, were excluded from the study.
A questionnaire which included height, weight, body mass index, history of infertility and menstrual status was filled for all participants before the start of the study and also 2 months post treatment with vitamin D. Fasting glucose, fasting insulin and 25-hydroxyvitamin D (25 (OH) D) levels were measured in all patients using a morning blood sample which was taken after a 12-hour overnight fast. We used a chemiluminescence immunoassay system to determine the serum insulin levels (Diasorin, Stillwater, MN, USA) and 25 (OH) D (DiaSorin SpA, Saluggia, Italy). The serum glucose levels were measured using a spectrophotometric method. All participants were then given a single dose of vitamin D (300,000 units) intramuscular and all tests were repeated again two months post treatment in the same manner. In addition, we calculated the glucose resistance index for all participants pretreatment and two months post-treatment. Insulin resistance was measured using the HOMA-IR method (Ardabili et al., 2012) . The patients were advised to avoid taking vitamin D or calcium supplements during the study. The body mass index was calculated by weight in kilograms divided by the square of the height in meters (kg/m 2 ).
Statistical Methods
The normality of the response variables (vitamin D, fasting blood sugar, insulin, insulin resistance, insulin sensitivity index) was checked using the Kolmogorov Smirnov formula and the paired t-test was used to compare pre and post treatment readings if normality was established. For adjusting the effects of possible confounding parameters (age, Body Mass Index -BMI, initial vitamin D level) we repeated the measure analysis of variance (ANOVA) if data had normal distribution, and non-parametric tests, like the Wilcoxon test, were used if the data did not have normal distribution. All statistical tests were performed using the SPSS software version 24 (Armonk, NY: IBM Corp.). p-values below 0.05 were considered statistically significant.
Sample size calculation was performed using these parameters: given a type I error of 0.05 and power of 80% with effect size of 1.5 points change in the HOMA-IR based on the study by Ardabili et al. (2012) a sample size of 38 was calculated. We entered 41 patients to cover for probable patients lost on follow up.
RESULTS
In total 41 patients with a mean age of 26.6±4.1 entered the study. All patients completed the study and no patient was lost on follow up. The minimum age was 20 and the maximum age was 36 years. The mean duration of infertility was 4.1±3.2 years and the mean weight and height were 67±12 kilograms and 161±5 cm, respectively (Table 1) .
The mean BMI was 25.7±4.4. Other demographic findings of participants including their place of residence, menstruation and hirsutism findings are summarized in Table 2 .
The main findings of the study are summarized in Table 3 . The vitamin D serum level significantly raised from a pretreatment mean of 5.07±1.77ng/mL to a post-treatment mean of 16.34±8.99ng/mL (p<0.001). The mean fasting blood glucose reading significantly decreased from 109.56±14.59mg/dL pretreatment to 103.71±13.72mg/dL post treatment (p=0.003). There was a significant decrease in the mean fasting serum insulin, from 8.52±5.48µU/mL pretreatment with vitamin D to 7.07±5.03 µU/mL post-treatment (p=0.019). The mean HOMA-IR, as a sign of insulin resistance, significantly decreased from 2.37±1.76 to 1.87±1.49, indicating lower insulin resistance (p=0.004).
DISCUSSION
It has been indicated that among women with PCOS, those with vitamin D deficiency are more likely to have dysglycemia, when compared to those without vitamin D deficiency (He et al., 2105) . Similarly, lower vitamin D levels have been related to abnormalities in glucose and insulin metabolism (Ardabili et al., 2012; Liu et al., 2009; Need et al., 2005) , so we chose women with PCOS and low levels of vitamin D to see if a single dose supplementation with vitamin D can improve their glucose metabolism and insulin resistance.
There are several non-placebo controlled trials of vitamin D treatment on glucose metabolism among women with PCOS, with inconsistent results. In the present study, 1 intramuscular dose of cholecalciferol (300,000 IU) after 2 months caused significant reduction in insulin resistance, as per indicated by HOMA-IR among women with PCOS and vitamin D deficiency. Similar to our findings, a study by Selimoglu et al. on 11 insulin-resistant women with PCOS, reported that HOMA-IR significantly decreased three weeks after the administration of a single dose (300,000 IU) of cholecalciferol (Selimoglu et al., 2010) . In our study the reduction in glucose and insulin levels were both statistically significant; however, Selimoglu et al., reported a non-significant reduction of glucose and insulin levels among their patients (Selimoglu et al., 2010) . In another study by Wehr et al., fifty-seven PCOS women received 20,000 IU of cholecalciferol weekly for 24 weeks (Wehr et al., 2009) . Anthropometric measures, oral glucose tolerance test, and blood analyses of endocrine parameters were performed at baseline and after 12 weeks and 24 weeks. They reported a significant decrease of fasting and stimulated glucose (p<0.05) and C-peptide levels (p<0.001) after vitamin D treatment (Wehr et al., 2009 ). Asemi et al. studied the effects of calcium plus vitamin D supplementation on glucose metabolism and lipid concentrations in overweight and obese vitamin D-deficient women with PCOS (Asemi et al., 2015) . They found that co-supplementation, led to decreased serum insulin levels (p=0.03), homeostasis model of assessment of the insulin-resistance (HOMA-IR) score (p=0.04), and a significant rise in the quantitative insulin-sensitivity check index (QUICKI) (p=0.001) (Asemi et al., 2015) .
In contrast in a study by Pal et al. (2012) , twelve overweight and vitamin D deficient women with PCOS underwent a 2-hour oral glucose tolerance testing at baseline and following 3 month supplementation with vitamin D (daily dose of 3533 IU, increased to 8533 IU after the first 5 participants) and 530mg elemental Ca daily. They assessed plasma glucose, insulin, and insulin-resistance, and reported that the parameters of glucose homeostasis and insulin resistance remained unchanged (p>0.05). Also Kotsa et al. (2009) reported that treatment with alfacalcidol in patients with PCOS caused no statistically significant change in insulin sensitivity. In another study, Ardabili et al. evaluated the effects of vitamin D supplementation on insulin resistance in women with PCOS and vitamin D deficiency (Ardabili et al., 2012) . In their study, the patients received 3 oral treatments consisting of 50,000 IU of vitamin D₃ (the case group) or a placebo (1 every 20 days) for 2 months. The fasting serum insulin and glucose levels and the insulin sensitivity and homeostasis model assessment of insulin resistance did not show a significant difference by the end of the study (Ardabili et al., 2012) . Raja-Khan et al. (2014) studied the effects of high-dose vitamin D on insulin sensitivity in polycystic ovary syndrome (PCOS). They reported that insulin sensitivity was unchanged with high-dose vitamin D, but there was a trend toward decreased 2-hour insulin levels.
Our study had some limitations. We did not use the glucose clamp method (Ardabili et al., 2012) , and we used the fasting level for evaluation of insulin sensitivity and secretion. Although we had a relatively small sample size, the significant results found in our study showed that the sample size seemed to be sufficient, and also we did not restrict our population to normal BMI, to avoid the confounding effect of weight loss after treatment, but we did not have significant weight loss in our study. Considering the controversial results of different studies in reducing the insulin resistance among PCOS women after supplementation with vitamin D, further experimentation with different doses of vitamin D and a longer intervention time are suggested in vitamin D-deficient women with PCOS to better support our findings.
In conclusion, it seems that a single injection of vitamin D significantly decreases serum insulin levels and insulin resistance among patients with polycystic ovary syndrome.
